USA flag logo/image

An Official Website of the United States Government

Zebrafish Assay for Cholesterol and Lipid Lowering Drugs

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66398
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
DK064472
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ZYGOGEN, LLC
58 Edgewood Avenue 1st Floor, Room 122 ATLANTA, GA 30303
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Zebrafish Assay for Cholesterol and Lipid Lowering Drugs
Agency: HHS
Contract: 1R43DK064472-01
Award Amount: $186,760.00
 

Abstract:

DESCRIPTION (provided by applicant): High levels of low density lipoprotein (LDL), cholesterol and triglycerides have been associated with an increase in cardiovascular disease. Drugs such as cholesterol-lowering statins and triglyceride-lowering fibrates have led to a reduction in coronary heart disease. Although current drugs have enjoyed some success, a need exists for improved lipid management and reduced side effects. Zygogen is developing a novel in vivo approach to identifying potential lipid-lowering drugs using Zebrafish, called Z-Lipotrack. Lipid processing is highly conserved in the Zebrafish. Because Zebrafish larvae are essentially transparent, lipid processing can be readily observed in the whole organism, with the aid of fluorescent lipid reporters. The goal of the proposed research is to develop Z-Lipotrack technology for use in high throughput compound screening, with the ultimate aim of discovering better drugs for lowering lipid levels. The proposed work will validate Z-Lipotrack as a compound screening tool. This includes testing additional control compounds, characterizing compounds identified in a small but diverse library of marketed drugs, and quantifying the fluorescent read-out in an automated fashion. Due to the high fecundity of Zebrafish, high throughput drug screening using Zebrafish larvae is feasible and could dramatically increase the chances of finding important new drugs.

Principal Investigator:

Amy L. Rubinstein
4045237309
AMY@ZYGOGEN.COM

Business Contact:

Nina Sawczuk
4045237309
NINA@ZYGOGEN.COM
Small Business Information at Submission:

ZYGOGEN, LLC
ZYGOGEN, LLC KELL HALL 520 ATLANTA, GA 30303

EIN/Tax ID: 582484200
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No